COMMUNIQUÉS West-GlobeNewswire

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
InspireMD to Announce Second Quarter 2026 Financial Results
10/08/2026
MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced it will issue its [...]
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer [...]
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
10/08/2026
Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 [...]
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
10/08/2026
- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/08/2026
WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to [...]
Mesa Labs Announces First Quarter Results
10/08/2026
LAKEWOOD, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
10/08/2026
Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting Announced a [...]
HRC Technology Solutions LLC Achieves SOC 1 Type 2 and SOC 2 Type 2 Compliance, Reinforcing Secure, AI-Driven Revenue Cycle Management
10/08/2026
SOUTHLAKE, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- HRC Technology Solutions LLC today announced it has achieved SOC 1 Type 2 and SOC 2 Type 2 compliance, independently assessed by ControlCase as its Qualified Security [...]
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
10/08/2026
The reported resubmission of the New Drug Application will initiate a new evaluation of the treatment’s safety and efficacy for potential FDA approval Recently updated FDA guidance, Psychedelic Drugs: Considerations for [...]
Dallas Hair Replacement for Business Professionals Offers Non-Surgical Hair Replacement for Men
10/08/2026
Look Sharp, Stay Competitive. Restore your confidence with non-surgical hair replacement in Dallas. Dallas, TX, Aug. 10, 2026 (GLOBE NEWSWIRE) -- In the competitive business environment of Dallas, confidence and success [...]
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
10/08/2026
Q2 Revenue of $9.1 million Q2 Income from Continuing Operations of $0.3 million Q2 Thyroid volume year-over-year increase of 6% Q2 Thyroid revenue year-over-year increase of 9% Trailing twelve-month thyroid revenue of $ [...]
Essential Amino Acid Intake Draws Focus During GLP-1 Therapy as Oh!mino Targets Muscle Loss
10/08/2026
Seal Beach, CA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Oh!Nutrition, a California-based nutritional product development company, today announced Oh!mino® Muscle Synthesis Activator, an essential amino acid supplement [...]
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08/2026
Initiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the planned Phase 2 [...]
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
10/08/2026
Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle) Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a [...]
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
10/08/2026
Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient for Phase 2 [...]
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
10/08/2026
The BACKBEAT global pivotal trial (“BACKBEAT Trial”), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data presentation [...]
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
10/08/2026
Antwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of [...]

Pages